Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.60
-0.06 (-0.69%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Karyopharm Therapeutics stock have an average target of 16, with a low estimate of 8.00 and a high estimate of 28. The average target predicts an increase of 86.05% from the current stock price of 8.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $8 → $16 | Buy | Reiterates | $8 → $16 | +86.05% | Apr 27, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 → $8 | Buy | Reiterates | $12 → $8 | -6.98% | Mar 30, 2026 |
| Baird | Baird | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +74.42% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $8 | Strong Buy | Maintains | $15 → $8 | -6.98% | Mar 25, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +225.58% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
140.24M
from 146.07M
Decreased by -3.99%
Revenue Next Year
171.60M
from 140.24M
Increased by 22.36%
EPS This Year
-4.54
from -17.93
EPS Next Year
-3.66
from -4.54
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 165.7M | 198.6M | ||||||
| Avg | 140.2M | 171.6M | ||||||
| Low | 127.4M | 142.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 13.4% | 41.6% | ||||||
| Avg | -4.0% | 22.4% | ||||||
| Low | -12.8% | 1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.33 | -1.91 | ||||||
| Avg | -4.54 | -3.66 | ||||||
| Low | -6.10 | -6.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.